In a PD experimental model, peripheral myeloid cell-derived GSDMD boosts microglial immune training via a mechanism where IL-1β, crossing the blood-brain barrier, triggers microglial cell polarization, thereby amplifying neuroinflammation and neurodegeneration. The gene discussed is IL1B; the disease is Parkinson disease.